Eva Corey

List of Publications by Year
in descending order

141 papers	9,146 citations	46918 47 h-index	49773 87 g-index
152 all docs	152 docs citations	152 times ranked	12092 citing authors

#	Article	IF	Citations
1	Tumor-induced anorexia and weight loss are mediated by the TGF-Î² superfamily cytokine MIC-1. Nature Medicine, 2007, 13, 1333-1340.	15.2	489
2	Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. Cancer Cell, 2017, 32, 474-489.e6.	7.7	483
3	Basic Mechanisms Responsible for Osteolytic and Osteoblastic Bone Metastases: Fig. 1.. Clinical Cancer Research, 2006, 12, 6213s-6216s.	3.2	444
4	The Androgen-Regulated Protease TMPRSS2 Activates a Proteolytic Cascade Involving Components of the Tumor Microenvironment and Promotes Prostate Cancer Metastasis. Cancer Discovery, 2014, 4, 1310-1325.	7.7	389
5	Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. Journal of Clinical Investigation, 2019, 129, 4492-4505.	3.9	250
6	Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway. Current Cancer Drug Targets, 2009, 9, 237-249.	0.8	244
7	Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 17087-17092.	3.3	233
8	Osteoprotegerin and rank ligand expression in prostate cancer. Urology, 2001, 57, 611-616.	0.5	222
9	Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. Nature Communications, 2014, 5, 4988.	5.8	219
10	LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease anÂÂd Serve as Models for Evaluating Cancer Therapeutics. Prostate, 2017, 77, 654-671.	1.2	219
11	Androgen Receptor Splice Variants Determine Taxane Sensitivity in Prostate Cancer. Cancer Research, 2014, 74, 2270-2282.	0.4	217
12	Establishment and characterization of osseous prostate cancer models: Intra-tibial injection of human prostate cancer cells. Prostate, 2002, 52, 20-33.	1.2	181
13	Prostate cancer reactivates developmental epigenomic programs during metastatic progression. Nature Genetics, 2020, 52, 790-799.	9.4	174
14	Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clinical Cancer Research, 2003, 9, 295-306.	3.2	174
15	Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress. Cell Reports, 2020, 31, 107669.	2.9	167
16	A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening. Clinical Cancer Research, 2018, 24, 4332-4345.	3.2	154
17	LuCaP 35: A new model of prostate cancer progression to androgen independence. Prostate, 2003, 55, 239-246.	1.2	141
18	Ferroptosis Inducers Are a Novel Therapeutic Approach for Advanced Prostate Cancer. Cancer Research, 2021, 81, 1583-1594.	0.4	140

#	Article	IF	Citations
19	Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models. Clinical Cancer Research, 2017, 23, 4335-4346.	3.2	138
20	SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2015, 21, 4698-4708.	3.2	137
21	Metastatic Progression of Prostate Cancer and E-Cadherin. American Journal of Pathology, 2011, 179, 400-410.	1.9	133
22	ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis. Nature Medicine, 2018, 24, 1887-1898.	15.2	113
23	Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate, 2003, 56, 13-22.	1.2	99
24	Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. Cell Reports, 2017, 19, 2045-2059.	2.9	99
25	Osteoprotegerin in Prostate Cancer Bone Metastasis. Cancer Research, 2005, 65, 1710-1718.	0.4	98
26	Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E4473-E4482.	3.3	96
27	Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone. Clinical and Experimental Metastasis, 2009, 26, 161-169.	1.7	95
28	Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases. Clinical and Experimental Metastasis, 2008, 25, 377-388.	1.7	91
29	A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer. Oncogene, 2019, 38, 4977-4989.	2.6	80
30	Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer. Nature Genetics, 2020, 52, 1011-1017.	9.4	78
31	Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patientâ€derived xenograft (PDX) models. Prostate, 2018, 78, 1262-1282.	1.2	76
32	Metastases of prostate cancer express estrogen receptor-beta. Urology, 2004, 64, 814-820.	0.5	73
33	THE VALUE OF A REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION ASSAY IN PREOPERATIVE STAGING AND FOLLOWUP OF PATIENTS WITH PROSTATE CANCER. Journal of Urology, 1998, 159, 1134-1138.	0.2	71
34	Radium-223 mechanism of action: implications for use in treatment combinations. Nature Reviews Urology, 2019, 16, 745-756.	1.9	71
35	Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. Nature Communications, 2021, 12, 1979.	5.8	70
36	Prostatic cell lineage markers: Emergence of BCL2+ cells of human prostate cancer xenograft LuCaP 23 following castration. , 1996, 65, 85-89.		67

#	Article	IF	Citations
37	Supraphysiological androgens suppress prostate cancer growth through androgen receptorâ€“mediated DNA damage. Journal of Clinical Investigation, 2019, 129, 4245-4260.	3.9	67
38	RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. Prostate, 2008, 68, 861-871.	1.2	64
39	Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) Messages. Urology, 1997, 50, 184-188.	0.5	63
40	A ribonucleoprotein octamer for targeted siRNA delivery. Nature Biomedical Engineering, 2018, 2, 326-337.	11.6	63
41	Targeting Factors Involved in Bone Remodeling as Treatment Strategies in Prostate Cancer Bone Metastasis. Clinical Cancer Research, 2006, 12, 6285s-6290s.	3.2	62
42	Nemoâ€like kinase induces apoptosis and inhibits androgen receptor signaling in prostate cancer cells. Prostate, 2009, 69, 1481-1492.	1.2	62
43	Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling. PLoS ONE, 2013, 8, e78881.	1.1	60
44	High-Affinity Peptide Ligands to Prostate-Specific Antigen Identified by Polysome Selection. Biochemical and Biophysical Research Communications, 1997, 232, 578-582.	1.0	59
45	Role of WNT7B-induced Noncanonical Pathway in Advanced Prostate Cancer. Molecular Cancer Research, 2013, 11, 482-493.	1.5	59
46	Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nature Communications, 2021, 12, 5775.	5.8	59
47	MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets. Nature Communications, 2022, 13, 2559.	5.8	56
48	Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: Results from the University of Washington Rapid Autopsy Series. Journal of Bone and Mineral Research, 2013, 28, 333-340.	3.1	55
49	Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases. Prostate, 2013, 73, 932-940.	1.2	53
50	Bone Morphogenetic Protein 7 Is Expressed in Prostate Cancer Metastases and Its Effects on Prostate Tumor Cells Depend on Cell Phenotype and the Tumor Microenvironment. Neoplasia, 2010, 12, 192-205.	2.3	52
51	Rapid Loss of RNA Detection by In Situ Hybridization in Stored Tissue Blocks and Preservation by Cold Storage of Unstained Slides. American Journal of Clinical Pathology, 2017, 148, 398-415.	0.4	52
52	Cellular Adhesion Promotes Prostate Cancer Cells Escape from Dormancy. PLoS ONE, 2015, 10, e0130565.	1.1	48
53	Identification of differentially expressed prostate genes: Increased expression of transcription factor ETS-2 in prostate cancer. , 1997, 30, 145-153.		47
54	The androgen receptor regulates a druggable translational regulon in advanced prostate cancer. Science Translational Medicine, 2019, 11, .	5.8	47

#	Article	IF	Citations
55	Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2019, 25, 426-439.	3.2	46
56	Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts. European Urology, 2020, 77, 144-155.	0.9	46
57	Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer. Prostate, 2016, 76, 810-822.	1.2	45
58	Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer. BMC Cancer, 2010, 10, 244.	1.1	44
59	Detection of disseminated prostate cells by reverse transcription-polymerase chain reaction (RT-PCR): Technical and clinical aspects. , 1998, 77, 655-673.		43
60	Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis. Clinical Cancer Research, 2018, 24, 5458-5470.	3.2	43
61	The expression of osteoclastogenesisâ€associated factors and osteoblast response to osteolytic prostate cancer cells. Prostate, 2010, 70, 412-424.	1.2	42
62	Downregulation of <i>Dipeptidyl Peptidase 4</i> Accelerates Progression to Castration-Resistant Prostate Cancer. Cancer Research, 2018, 78, 6354-6362.	0.4	42
63	When prostate cancer meets bone: Control by wnts. Cancer Letters, 2007, 253, 170-179.	3.2	41
64	Characterization of C4-2 Prostate Cancer Bone Metastases and Their Response to Castration. Journal of Bone and Mineral Research, 2003, 18, 1882-1888.	3.1	40
65	Expression of the human cachexia-associated protein (HCAP) in prostate cancer and in a prostate cancer animal model of cachexia. International Journal of Cancer, 2003, 105, 123-129.	2.3	40
66	Inhibition of androgen-independent growth of prostate cancer xenografts by 17beta-estradiol. Clinical Cancer Research, 2002, 8, 1003-7.	3.2	40
67	HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer. Nature Genetics, 2022, 54, 670-683.	9.4	39
68	AR-Regulated TWEAK-FN14 Pathway Promotes Prostate Cancer Bone Metastasis. Cancer Research, 2014, 74, 4306-4317.	0.4	37
69	Inhibition of CCL2 Signaling in Combination with Docetaxel Treatment Has Profound Inhibitory Effects on Prostate Cancer Growth in Bone. International Journal of Molecular Sciences, 2013, 14, 10483-10496.	1.8	35
70	Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5â€“SN38 Antibodyâ€“drug Conjugate in Neuroendocrine Prostate Cancer. Clinical Cancer Research, 2021, 27, 759-774.	3.2	34
71	Rapid modification of the bone microenvironment following short-term treatment with Cabozantinib in vivo. Bone, 2015, 81, 581-592.	1.4	33
72	Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions. Cancers, 2017, 9, 166.	1.7	33

#	Article	IF	Citations
73	Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibodyâ€"Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer. Molecular Cancer Therapeutics, 2018, 17, 2176-2186.	1.9	33
74	The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 661-669.	2.0	33
75	BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program. Clinical Cancer Research, 2021, 27, 4923-4936.	3.2	33
76	Efficacy studies of an antibodyâ€drug conjugate PSMAâ€ADC in patientâ€derived prostate cancer xenografts. Prostate, 2015, 75, 303-313.	1.2	31
77	Circular RNAs add diversity to androgen receptor isoform repertoire in castration-resistant prostate cancer. Oncogene, 2019, 38, 7060-7072.	2.6	31
78	Taxane resistance in prostate cancer is mediated by decreased drug-target engagement. Journal of Clinical Investigation, 2020, 130, 3287-3298.	3.9	31
79	Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer. Clinical Cancer Research, 2020, 26, 1667-1677.	3.2	30
80	Multiplexed functional genomic analysis of 5â€™ untranslated region mutations across the spectrum of prostate cancer. Nature Communications, 2021, 12, 4217.	5.8	30
81	Inhibition of angiopoietinâ€2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability. Prostate, 2010, 70, 1799-1808.	1.2	29
82	Prostate cancer cell phenotypes based on AGR2 and CD10 expression. Modern Pathology, 2013, 26, 849-859.	2.9	29
83	High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer. Scientific Reports, 2018, 8, 17239.	1.6	29
84	Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis. Clinical Cancer Research, 2022, 28, 928-938.	3.2	29
85	Inhibition of Androgen-Independent Prostate Cancer by Estrogenic Compounds Is Associated with Increased Expression of Immune-Related Genes. Neoplasia, 2006, 8, 862-878.	2.3	28
86	A novel method of generating prostate cancer metastases from orthotopic implants. Prostate, 2003, 56, 110-114.	1.2	27
87	Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression. Nature Communications, 2021, 12, 7033.	5.8	27
88	Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers. International Journal of Cancer, 2006, 118, 222-229.	2.3	26
89	Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer. Prostate, 2016, 76, 325-334.	1.2	25
90	Gambogic acid inhibits thioredoxin activity and induces ROS-mediated cell death in castration-resistant prostate cancer. Oncotarget, 2017, 8, 77181-77194.	0.8	25

#	Article	IF	Citations
91	Targeting RET Kinase in Neuroendocrine Prostate Cancer. Molecular Cancer Research, 2020, 18, 1176-1188.	1.5	23
92	Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth. Journal of Clinical Investigation, 2021, 131, .	3.9	23
93	Identifying Dysregulated Epigenetic Enzyme Activity in Castrate-Resistant Prostate Cancer Development. ACS Chemical Biology, 2017, 12, 2804-2814.	1.6	22
94	<i>COMMD3:BMI1</i> Fusion and COMMD3 Protein Regulate <i>C-MYC</i> Transcription: Novel Therapeutic Target for Metastatic Prostate Cancer. Molecular Cancer Therapeutics, 2019, 18, 2111-2123.	1.9	22
95	Androgen receptor-induced integrin Î±6Î²1 and Bnip3 promote survival and resistance to PI3K inhibitors in castration-resistant prostate cancer. Oncogene, 2020, 39, 5390-5404.	2.6	22
96	Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer. JCI Insight, 2021, 6, .	2.3	22
97	HE3235 Inhibits Growth of Castration-Resistant Prostate Cancer. Neoplasia, 2009, 11, 1216-IN23.	2.3	21
98	Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment. Clinical and Experimental Metastasis, 2014, 31, 247-256.	1.7	21
99	Paracrine sonic hedgehog signaling contributes significantly to acquired steroidogenesis in the prostate tumor microenvironment. International Journal of Cancer, 2017, 140, 358-369.	2.3	21
100	LNCaP produces both putative zymogen and inactive, free form of prostate-specific antigen. , 1998, 35, 135-143.		20
101	Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts. Clinical Cancer Research, 2017, 23, 2301-2312.	3.2	20
102	MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer. Scientific Reports, 2021, 11, 13305.	1.6	20
103	Characterization of 10 new monoclonal antibodies against prostate-specific antigen by analysis of affinity, specificity and function in sandwich assays. , 1997, 71, 1019-1028.		19
104	Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4. Neoplasia, 2020, 22, 253-262.	2.3	19
105	Inhibition of ERG Activity in Patient-derived Prostate Cancer Xenografts by YK-4-279. Anticancer Research, 2017, 37, 3385-3396.	0.5	19
106	RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer. Cancer Research, 2021, 81, 4736-4750.	0.4	18
107	Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155. Molecular Cancer Research, 2017, 15, 521-531.	1.5	17
108	Increased transcription and high translation efficiency lead to accumulation of androgen receptor splice variant after androgen deprivation therapy. Cancer Letters, 2021, 504, 37-48.	3.2	17

#	Article	IF	Citations
109	Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer. Clinical and Experimental Metastasis, 2016, 33, 325-337.	1.7	16
110	Differential expression of Î±VÎ²3 and Î±VÎ²6 integrins in prostate cancer progression. PLoS ONE, 2021, 16, e0244985.	1.1	16
111	Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer. JCI Insight, 2021, 6, .	2.3	15
112	A bladderÂcancerÂpatient-derived xenograft displays aggressive growth dynamics in vivo and in organoid culture. Scientific Reports, 2021, 11, 4609.	1.6	14
113	Establishing a cryopreservation protocol for patientâ€derived xenografts of prostate cancer. Prostate, 2019, 79, 1326-1337.	1.2	12
114	Antitumor Activity of the IGF-1/IGF-2â€"Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models. Molecular Cancer Therapeutics, 2020, 19, 1059-1069.	1.9	12
115	Reciprocal <scp>YAP1</scp> loss and <scp>INSM1</scp> expression in neuroendocrine prostate cancer. Journal of Pathology, 2021, 255, 425-437.	2.1	12
116	Small extracellular vesicle-mediated <i>ITGB6</i> siRNA delivery downregulates the Î±VÎ²6 integrin and inhibits adhesion and migration of recipient prostate cancer cells. Cancer Biology and Therapy, 2022, 23, 173-185.	1.5	12
117	Cross-reactivity of ten anti-prostate-specific antigen monoclonal antibodies with human glandular kallikrein. Urology, 1997, 50, 567-572.	0.5	11
118	Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer. Frontiers in Oncology, 2018, 8, 167.	1.3	11
119	Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2022, 28, 3127-3140.	3.2	11
120	Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer. Clinical Cancer Research, 2022, 28, 3509-3525.	3.2	11
121	Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer. Molecular Therapy, 2022, 30, 1628-1644.	3.7	10
122	Targeting Feedforward Loops Formed by Nuclear Receptor RORÎ³ and Kinase PBK in mCRPC with Hyperactive AR Signaling. Cancers, 2021, 13, 1672.	1.7	9
123	Response to supraphysiological testosterone is predicted by a distinct androgen receptor cistrome. JCI Insight, 2022, 7, .	2.3	9
124	CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells. International Journal of Oncology, 2015, 46, 1560-1572.	1.4	7
125	Generation of Prostate Cancer Patient-Derived Xenografts to Investigate Mechanisms of Novel Treatments and Treatment Resistance. Methods in Molecular Biology, 2018, 1786, 1-27.	0.4	7
126	Hypoxia-induced PIM kinase and laminin-activated integrin Î±6 mediate resistance to PI3K inhibitors in bone-metastatic CRPC. American Journal of Clinical and Experimental Urology, 2019, 7, 297-312.	0.4	7

#	Article	IF	Citations
127	Low dose, alternating electric current inhibits growth of prostate cancer. Prostate, 2010, 70, 529-539.	1.2	6
128	Magnetoâ€Endosomalytic Therapy for Cancer. Advanced Healthcare Materials, 2022, 11, e2101010.	3.9	6
129	Prostate Cancer Characteristics Associated with Response to Pre-Receptor Targeting of the Androgen Axis. PLoS ONE, 2014, 9, e111545.	1.1	6
130	Study of free and complexed prostate-specific antigen in mice bearing human prostate cancer xenografts. , 1998, 36, 194-200.		5
131	Lineage relationship between prostate adenocarcinoma and small cell carcinoma. BMC Cancer, 2019, 19, 518.	1.1	5
132	Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature. PLoS ONE, 2021, 16, e0245602.	1.1	5
133	Telomere lengths differ significantly between small-cell neuroendocrine prostate carcinoma and adenocarcinoma of the prostate. Human Pathology, 2020, 101, 70-79.	1.1	5
134	Inhibition of Serum Response Factor Improves Response to Enzalutamide in Prostate Cancer. Cancers, 2020, 12, 3540.	1.7	4
135	Proteomic and Transcriptomic Profiling Reveals Mitochondrial Oxidative Phosphorylation as Therapeutic Vulnerability in Androgen Receptor Pathway Active Prostate Tumors. Cancers, 2022, 14, 1739.	1.7	4
136	GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models. Clinical Cancer Research, 2016, , clincanres.0137.2016.	3.2	3
137	Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155. Molecular Cancer Research, 2017, 15, 521-531.	1.5	3
138	Data of relative mRNA and protein abundances of androgen receptor splice variants in castration-resistant prostate cancer. Data in Brief, 2021, 34, 106774.	0.5	2
139	Altered glucuronidation deregulates androgen dependent response profiles and signifies castration resistance in prostate cancer. Oncotarget, 2021, 12, 1886-1902.	0.8	2
140	FOXA2 promotes prostate cancer growth in the bone. American Journal of Translational Research (discontinued), 2020, 12, 5619-5629.	0.0	1
141	Estrogen in Prostate Cancer - Friend or Foe?. Current Cancer Therapy Reviews, 2006, 2, 341-349.	0.2	0